Navigation Links
Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
Date:7/21/2008

LONDON, July 21 /PRNewswire/ -- The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) proposed that the hypothesis-generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE-IT trials of ezetimibe, and reporting on the overall findings to the relevant regulatory authorities, independently of the drug manufacturers.

The two hypothesis-testing trials (SHARP and IMPROVE-IT) contain about four times as many cancers as the SEAS trial. They do not confirm the hypothesis raised by the SEAS trial that treatment increases the overall risk of developing cancer. In addition, there is no increase with time in the relative risk (active vs placebo) suggested by the cancer incidence and mortality from all 3 trials together (or just from the pair of hypothesis-testing trials). Consequently, the SEAS, SHARP and IMPROVE-IT trials do not provide credible evidence of any adverse effect on cancer.

Allocation to 5 years of substantial LDL-cholesterol lowering by a statin has been shown previously to have no apparent effect on cancer. The Cholesterol Treatment Trialists' collaboration has published results (Lancet 2005;366: 1267-78) based on 90,000 patients randomised evenly between statin and control. Based on 5530 patients with cancer onset after randomisation, the statin vs control relative risk was 0.997 (with 95% confidence interval 0.95-1.05; not significant). Of these patients, 2163 died of their cancer during the scheduled follow-up period; the relative risk for cancer death was 1.01 (with 95% confidence interval 0.91-1.12; not significant).

In the final results from the SEAS trial, there appears to be a small increase in total cancer incidence in the group allocated ezetimibe + statin, but this is based on only 102 vs 67 cancer cases (including 39 vs 23 fatal cases) and there is no significant increase in any particular type of cancer.

Two other large trials of ezetimibe + statin are still in progress: (i) SHARP (ezetimibe + simvastatin vs placebo in 9,000 patients; recruitment completed, but treatment and follow-up continuing) and (ii) IMPROVE-IT (ezetimibe + simvastatin vs placebo + simvastatin in 11,000 patients; recruitment continues towards an eventual target of 18,000 patients). Together, they have already accumulated about four times as many cancers as SEAS (see table). If treatment really did increase total cancer by 50% then this would have been clearly apparent in the hypothesis testing SHARP & IMPROVE-IT trials. Instead, there was no evidence of any increase in cancer (see table).

Cancer events Active Control

Hypothesis generator: SEAS 102 67

Hypothesis test: SHARP & IMPROVE-IT* 313 326

* 216 active vs 254 control non-fatal cases and 97 vs 72 fatal cases.

If there were a real adverse effect on cancer incidence or cancer mortality then previous experience with the epidemiology of cancer (ie, with other causes of the disease in humans) strongly suggests that the relative risk (active versus control) should grow bigger with time, but it does not, whether the hypothesis-testing trials are considered separately or all 3 trials are considered together.

Note: The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) has decades of experience in cancer epidemiology, in vascular and other trials, and in collaborative meta-analyses of trials. Although CTSU is conducting the SHARP trial, it is doing so independently of the source of funding, and has a policy of not accepting honoraria or consultancy fees. This report to regulatory authorities on the analyses of SEAS, SHARP and IMPROVE-IT was initiated, conducted and interpreted by the CTSU independently of any source of funding.

For more information, please, refer to the press release issued by the SEAS investigators today.

Contact: Andrew Trehearne, CTSU, +44(0)1865-743960, +44(0)789-404-2600

Co-directors: Rory Collins FMed Sci FRCP BHF Professor of Medicine and Epidemiology Sir Richard Peto FRS Hon FRCP Professor of Medical Statistics and Epidemiology

Jane Colin Jillian John Cairns Zhengming Michael

Armitage Baigent FFPH Boreham FRS Chen MBBS Clarke DPhil

FFPH FRCP FRCP PhD DPhil

Emeritus Professor of

Reader in Professor of Senior Professor Professor of Clinical

Clinical Epidemiology Research of Cancer Epidemiology Epidemiology

Epidemiology Fellow

Robert Sarah Darby Christina Alison Martin Christine

Clarke FFPH PhD Davies Halliday Landray PhD Marsden PhD

FRCP BMBCh MSc FRCS MRCP

Professor of Unit

Reader in Medical Senior Consultant Reader in Administra-

Epidemiology Statistics Research in Vascular Epidemiology tor

Fellow Surgery

Sarah Parish Max Parkin Susan David Alan Young Sarah Clark,

DPhil MD Richards Simpson OBE DPhil Karen

DPhil Hon MFPH Kourellias &

Senior Honorary Head of

Research Senior Senior Director, Systems Martin

Fellow Research Research IATH Development Radley: Lab

Fellow Fellow Management


'/>"/>
SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
Breaking Medicine News(10 mins):